Insilico Medicine news
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Boehringer Ingelheim to utilize Insilico`s generative machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying potential therapeutic targets implicated in a variety of diseases.
"Insilico Medicine is very impressed with the Research Beyond Borders gro
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.
Insilico`s PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico`s AI platform. The compound can be efficiently prepared with a two-step synthesis from commercial starting materials. I
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico`s machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.
"Insilico is advancing its latest target identification systems utilizing machine le
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico`s growing portfolio of synthetic lethality assets in development.
MTAP deletion is one of the most common
Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.
ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine`s end-to-end AI-powered drug discovery platform.